MOTS-c Half-Life: How Long It Stays in Your System
How long MOTS-c stays in the body, how that shapes dosing frequency, and what is known about drug testing.
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
- Dosing interval
- Varies by study
- as used in studies
- WADA
- Prohibited (S4.4.1)
- In and out of competition
- Detection window
- 1 finding
- from anti-doping studies, below
MOTS-c half-life
Half-life: no published half-life found (PubMed search, 11 Oct 2026). A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray), so we report it per route with the study it came from.
What half-life means
Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.
- A long half-life lets a drug be dosed less often, for example once a week.
- A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
- Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.
What it means for dosing frequency
Dosing intervals used in published studies of MOTS-c:
- repeated, n/a (Human RCT; Medicine and science in sports and exercise 2025, PMID 40674654)
- n/a, n/a (Human RCT; Aging 2022, PMID 36490309)
- n/a, n/a (Human RCT; Scientific reports 2021, PMID 34413391)
- single session, n/a (Human RCT; Journal of applied physiology 2021, PMID 34351816)
Changing the interval changes how much drug builds up between doses, so it is not a free choice.
Drug tests and sport
Prohibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times.
Detection findings from anti-doping analytical studies:
- A plasma (blood) test for MOTS-c has been validated to WADA standards. · PMID 30394592
Tested athletes should treat it as prohibited (s4.4.1) at all times.
Why no half-life is published
A review of mitochondria-derived peptides lists low bioavailability, poor stability and high synthesis costs as obstacles to clinical use.[15]
A detection method developed for doping control reached a lower limit of detection of 100 pg/mL for MOTS-c in plasma.[4]
Even natural levels are disputed
ELISA gave 45.9-218.5 ng/mL in 20 healthy subjects, but LC/MS could not confirm those endogenous levels.[4]
In a randomized exercise trial, plasma MOTS-c showed only a trend to rise after endurance exercise.[8]
Approval status
Drugs@FDA returns no MOTS-c product, so no label exists to give a half-life.[16]
How long MOTS-c stays in your system: no human clearance data
The doping-control assay paper tested the peptide's long-term stability and its metabolism in vitro, not its clearance in people, so it gives no elimination time.[4]
That assay also covers four metabolites made in vitro and two oxidation products, which the authors say might improve traceability.[4]
In a mouse colitis study, test-tube experiments found that a modified MOTS-c (MP, with a cell-penetrating tail added) had a longer half-life than MOTS-c itself; no figure is given in the abstract and this was not a human measurement.[17]
A recent rat-heart study says broader dosing and pharmacokinetic studies are needed before translational application.[18]
Common questions
How long does MOTS-c stay in your system?
We found no published half-life for MOTS-c (PubMed search, 11 Oct 2026). As a rule, most of a dose is cleared after about four to five half-lives.
What is the half-life of MOTS-c?
None is stated in the cached sources; reviews instead cite poor stability as a barrier.[15]
Is MOTS-c on the WADA prohibited list?
Yes. Prohibited by WADA (S4.4.1).
Is MOTS-c on the WADA list?
Yes: WADA's list names MOTS-c among the AMPK activators.[3]
Does MOTS-c show on a drug test?
A plasma test exists for MOTS-c, developed for doping control, with a lower limit of detection of 100 pg/mL.[4]
More on MOTS-c
Sources
- 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2Pharmacy Compounding Advisory Committee meeting, 23–24 Jul 2026 (agenda and materials)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 4Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
- 5Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
- 6Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
- 7Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
- 8Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans.Journal of applied physiology (Bethesda, Md. : 1985) · 2021PMID 34351816Accessed 2 Oct 2026
- 9PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 15Mitochondria‑derived peptides: Promising microproteins in cardiovascular diseases (Review).Molecular medicine reports · 2025PMID 40084698Accessed 5 Oct 2026
- 16Drugs@FDA (openFDA) search: active ingredient "MOTS-c"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 17Orally administered MOTS-c analogue ameliorates dextran sulfate sodium-induced colitis by inhibiting inflammation and apoptosis.European journal of pharmacology · 2023PMID 36528071Accessed 2 Oct 2026
- 18Exogenous MOTS-c mitigates myocardial ischemia-reperfusion injury: experimental and in silico evidence from rat heart models.Naunyn-Schmiedeberg's archives of pharmacology · 2026PMID 41593376Accessed 2 Oct 2026
Found an error? Report a correction.